1. Home
  2. DXR

as of 04-06-2026 3:59pm EST

$9.02
$0.68
-7.01%
Stocks Health Care Medical/Dental Instruments Nasdaq

Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.

Founded: 1970 Country:
United States
United States
Employees: N/A City: NEW YORK
Market Cap: 71.4M IPO Year: 1995
Target Price: N/A AVG Volume (30 days): 6.5K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield:
N/A
Dividend Payout Frequency: semi-annual
EPS: N/A EPS Growth: N/A
52 Week Low/High: $7.10 - $14.76 Next Earning Date: 02-27-2026
Revenue: $1,446,345 Revenue Growth: -8.42%
Revenue Growth (this year): 44935.22% Revenue Growth (next year): 74.79%
P/E Ratio: 33.83 Index: N/A
Free Cash Flow: -6631798.0 FCF Growth: N/A

AI-Powered DXR Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

hold
Model Accuracy: 68.28%
68.28%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Stock Insider Trading Activity of Daxor Corporation (DXR)

Michel Robert J

Chief Financial Officer

Buy
DXR Mar 31, 2026

Avg Cost/Share

$9.90

Shares

1,000

Total Value

$9,900.00

Owned After

21,050

SEC Form 4

Jefferies John

Chief Medical Officer

Buy
DXR Mar 20, 2026

Avg Cost/Share

$0.00

Shares

5,941

Total Value

$0.00

Owned After

21,272

Share on Social Networks: